Smallpox
📧 Sign up to get email alerts when something new happens for Smallpox.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-07EMA Authorised: Imvanex (modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus) — Bavarian Nordic A/S
EMA has authorised Imvanex (MVA-BN) vaccine from Bavarian Nordic A/S for smallpox and monkeypox indications.
-
EMA approval · 2026-06-15EMA Authorised: Tecovirimat SIGA (tecovirimat) — SIGA Technologies Netherlands B.V.
The EMA authorized tecovirimat (SIGA) for multiple poxvirus infections, including monkeypox and smallpox, under the marketing authorization …
-
EMA approval · 2025-11-10EMA Authorised: Tecovirimat SIGA (tecovirimat) — SIGA Technologies Netherlands B.V.
The EMA authorised tecovirimat (brand SIGA) for treatment of orthopoxvirus infections including cowpox, monkeypox, vaccinia infection, and s…
-
EMA approval · 2025-10-20EMA Authorised: Imvanex (modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus) — Bavarian Nordic A/S
EMA authorised Imvanex (MVA-BN) from Bavarian Nordic A/S for protection against smallpox and monkeypox, expanding its indications to include…
-
FDA approval · 2024-06-03FDA Approved: TPOXX — Supplemental Application (SIGA Technologies, Inc.)
FDA approves a supplemental application for TPOXX (tecovirimat monohydrate) from SIGA Technologies, expanding its approved use for smallpox.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-06-03FDA Approved: TPOXX — Supplemental Application (SIGA Technologies, Inc.)
FDA approved a supplemental application for TPOXX (tecovirimat monohydrate) submitted by SIGA Technologies, Inc. The supplement has been app…
-
FDA approval · 2022-05-18FDA Approved: TPOXX — Original Application (SIGA Technologies, Inc.)
The FDA approved TPOXX (tecovirimat monohydrate) from SIGA Technologies under original NDA 214518 for the treatment of smallpox in adults an…
-
FDA approval · 2022-05-18FDA Approved: TPOXX — Supplemental Application (SIGA Technologies, Inc.)
The FDA approved a supplemental application for TPOXX (tecovirimat monohydrate) submitted by SIGA Technologies, Inc. The action updates the …
-
FDA approval · 2021-08-03FDA Approved: TEMBEXA — Supplemental Application (Emergent BioDefense Operations Lansing LLC)
FDA approved a supplemental application for TEMBEXA (brincidofovir) submitted by Emergent BioDefense Operations Lansing LLC.
-
FDA approval · 2021-06-04FDA Approved: TEMBEXA — Original Application (Emergent BioDefense Operations Lansing LLC)
FDA approved TEMBEXA (brincidofovir) under the original NDA (NDA214460) for the treatment of smallpox (Variola virus), developed by Emergent…
-
FDA approval · 2021-06-04FDA Approved: TEMBEXA — Original Application (Emergent BioDefense Operations Lansing LLC)
FDA approves TEMBEXA (brincidofovir) from Emergent BioDefense Operations Lansing LLC under an original application for the prevention of sma…
-
FDA approval · 2018-07-13FDA Approved: TPOXX — Original Application (SIGA Technologies, Inc.)
FDA granted original approval for TPOXX (tecovirimat monohydrate) from SIGA Technologies for the treatment of smallpox due to variola virus.